secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2021-08-17T23:59:59+00:00
Accession:  0001628280-21-017175
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia licenses novel peptide AUR300 from Riptide for autoimmune/fibrotic diseases; $6M upfront
--------------------------------------------------------------------------------

- Global licensing/research pact with Riptide for peptide AUR300 targeting M2 macrophages via CD206 receptor.
- Aurinia pays $6M upfront; potential milestones and royalties on future sales of AUR300.
- AUR300 reduces M2 dysregulation and inflammatory cytokines, aiming to treat autoimmune and fibrotic diseases.
- Joint development committee formed; Riptide handles tech transfer and indication research activities.
- Deal expands Aurinia's pipeline beyond LUPKYNIS into fibrosis and other autoimmune conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828021017175/0001628280-21-017175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828021017175/auph-20210817.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-017175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer